Načítá se...
Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART)
BACKGROUND: Pharmacokinetic studies with XM17 (Ovaleap®), a recombinant human follicle-stimulating hormone (r-hFSH, follitropin alfa), have demonstrated good safety and tolerability in healthy women whose endogenous FSH levels were down-regulated with a long agonist protocol. In these studies, Ovale...
Uloženo v:
Vydáno v: | Reprod Biol Endocrinol |
---|---|
Hlavní autoři: | , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
BioMed Central
2016
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4702416/ https://ncbi.nlm.nih.gov/pubmed/26733057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12958-015-0135-8 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|